TG Therapeutics | TGTX - Ebit

Stock Price
30.36
Daily Change
0.32 1.07%
Monthly
2.81%
Yearly
-27.52%
Q1 Forecast
27.12

TG Therapeutics reported $50.49M in EBIT for its fiscal quarter ending in December of 2025.





Ebit Change Date
AbbVie USD 5.81B 4.36B Dec/2025
Alaunos Therapeutics USD -1.19M 148K Sep/2025
Amgen USD 3.96B 464M Dec/2025
Ardelyx USD 5.1M 2.02M Dec/2025
Arrowhead Research USD 40.81M 17.01M Dec/2025
Bayer EUR 1.11B 1.51B Dec/2025
Biogen USD 659.6M 157M Sep/2025
Corcept Therapeutics USD 4.49M 5.73M Dec/2025
Curis USD -12.37M 230K Sep/2023
Gilead Sciences USD 2.96B 551M Dec/2025
Infinity Pharmaceuticals USD -10.12M 1.39M Jun/2023
J&J USD 5.11B 2.3B Dec/2025
Karyopharm Therapeutics USD -26.28M 1.84M Sep/2024
Novartis USD -9.19B 13.87B Jun/2025
Novavax USD 20.94M 100.32M Dec/2025
PTC Therapeutics USD -81.62M 85.11M Dec/2025
Puma Biotechnology USD -2.2M 11.41M Jun/2024
Regeneron Pharmaceuticals USD 898.6M 211.3M Dec/2025
Roche Holding CHF 9.56B 2.1B Dec/2025
TG Therapeutics USD 50.49M 21.13M Dec/2025
Verastem USD -37.03M 6M Sep/2024
Vertex Pharmaceuticals USD 1.26B 24.5M Dec/2025